斯洛文尼亚 - 斯洛文尼亚文 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

bortezomib - prašek za raztopino za injiciranje - bortezomib 1 mg / 1 viala - bortezomib

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotična sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

斯洛文尼亚 - 斯洛文尼亚文 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

filmsko obložena tableta - ropinirol

斯洛文尼亚 - 斯洛文尼亚文 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

filmsko obložena tableta - ropinirol

斯洛文尼亚 - 斯洛文尼亚文 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

filmsko obložena tableta - ropinirol

斯洛文尼亚 - 斯洛文尼亚文 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mylan s.a.s. - vankomicin - prašek za raztopino za infundiranje - vankomicin 1000 mg / 1 viala - vankomicin

斯洛文尼亚 - 斯洛文尼亚文 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mylan s.a.s. - vankomicin - prašek za raztopino za infundiranje - vankomicin 1000 mg / 1 viala - vankomicin

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

viatris healthcare limited - imikvimod - condylomata acuminata; keratosis; keratosis, actinic; carcinoma, basal cell - antibiotiki in kemoterapevtiki za dermatološko uporabo - imiquimod cream is indicated for the topical treatment of :external genital and perianal warts (condylomata acuminata) in adults. small superficial basal cell carcinomas (sbccs) in adults. clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (aks) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

viatris healthcare limited - fenofibrate, simvastatin - dislipidemije - sredstva za spreminjanje lipidov - cholib je označen kot dodatno zdravljenje prehrana in telesno vadbo v visokim tveganjem kardiovaskularnih odraslih bolnikih z mešano dyslipidaemia za zmanjšanje trigliceridov in povečanje hdl c ravni, ko ravni ldl c ustrezno nadzorovana z ustreznim odmerkom simvastatin monoterapije.

欧盟 - 斯洛文尼亚文 - EMA (European Medicines Agency)

viatris limited - sildenafil citrat - hipertenzija, pljučnica - urološki - adultstreatment odraslih bolnikih s pljučne arterijske hipertenzije, ki so razvrščene kot funkcijski razred ii in iii, za izboljšanje vadbe zmogljivosti. učinkovitost je bila dokazana pri primarni pljučni hipertenziji in pljučni hipertenziji, povezani z boleznijo vezivnega tkiva. pediatrični populationtreatment pri pediatričnih bolnikih, starih od 1 leta do 17 let, s pljučne arterijske hipertenzije. učinkovitost v smislu izboljšanja telesne zmogljivosti ali pljučne hemodinamike je bila prikazana v primarni pljučni hipertenziji in pljučni hipertenziji, povezani s prirojeno srčno boleznijo (glejte poglavje 5.